How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C?

Journal of Viral Hepatitis

Volumn 19, Issue SUPPL. 1, 2012, Pages 18-32

  Sebastiani, G ^a   Alberti, A ^a,b  

^a VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

combination algorithms; hepatitis C; liver biopsy; liver fibrosis; noninvasive methods

Indexed keywords

ALGORITHM; ANTIVIRAL THERAPY; ARTICLE; ELASTOGRAPHY; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; NON INVASIVE PROCEDURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCREENING; STAGING; TREATMENT INDICATION;

ALGORITHMS; BIOLOGICAL MARKERS; BIOPSY; ELASTICITY IMAGING TECHNIQUES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; PRACTICE GUIDELINES AS TOPIC;

EID: 84855646420     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01518.x     Document Type: Article

References (93)

1. Anonymous. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6 (1): 35-47.
2. Seeff LB,. Natural history of chronic hepatitis C. Hepatology 2002; 5 (Suppl. 1): S35-S46. (Pubitemid 35253462)
3. Friedman SL,. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134 (6): 1655-1669. (Pubitemid 351615417)
4. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23 (6): 1334-1340. (Pubitemid 26181213)
5. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49 (4): 1335-1374.
6. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1 (5): 431-435. (Pubitemid 12218164)
7. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22 (6): 696-699.
8. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20 (1 Pt 1): 15-20.
9. Bedossa P, Poynard T,. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24 (2): 289-293. (Pubitemid 26260021)
10. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97 (10): 2614-2618.
11. Pagliaro L, Rinaldi F, Craxi A, et al. Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial. Dig Dis Sci 1983; 28 (1): 39-43. (Pubitemid 13223401)
12. Poniachik J, Bernstein DE, Reddy KR, et al. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc 1996; 43 (6): 568-571. (Pubitemid 26192224)
13. Colloredo G, Guido M, Sonzogni A, Leandro G,. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39 (2): 239-244. (Pubitemid 36920560)
14. Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41 (2): 257-264. (Pubitemid 40165369)
15. Afdhal NH, Nunes D,. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004; 99 (6): 1160-1174. (Pubitemid 38917824)
16. Sebastiani G, Alberti A,. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006; 12 (23): 3682-3694. (Pubitemid 43950946)
17. Guido M, Rugge M,. Liver biopsy sampling in chronic viral hepatitis. Semin Liver Dis 2004; 24 (1): 89-97. (Pubitemid 38496051)
18. Bedossa P, Dargere D, Paradis V,. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38 (6): 1449-1457. (Pubitemid 37466971)
19. Scheuer PJ,. Liver biopsy size matters in chronic hepatitis: bigger is better. Hepatology 2003; 38 (6): 1356-1358. (Pubitemid 37466959)
20. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD,. Liver biopsy. Hepatology 2009; 49 (3): 1017-1044.
21. Mehta SH, Lau B, Afdhal NH, Thomas DL,. Exceeding the limits of liver histology markers. J Hepatol 2009; 50 (1): 36-41.
22. Eisenberg E, Konopniki M, Veitsman E, Kramskay R, Gaitini D, Baruch Y,. Prevalence and characteristics of pain induced by percutaneous liver biopsy. Anesth Analg 2003; 96 (5): 1392-1396, table of contents. (Pubitemid 36512882)
23. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A,. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36 (3): 437-441.
24. Chevallier P, Ruitort F, Denys A, et al. Influence of operator experience on performance of ultrasound-guided percutaneous liver biopsy. Eur Radiol 2004; 14 (11): 2086-2091. (Pubitemid 39481182)
25. Bonny C, Rayssiguier R, Ughetto S, et al. [Medical practices and expectations of general practitioners in relation to hepatitis C virus infection in the Auvergne region]. Gastroenterol Clin Biol 2003; 27 (11): 1021-1025. (Pubitemid 37516827)
26. Almasio PL, Niero M, Angioli D, et al. Experts' opinions on the role of liver biopsy in HCV infection: a Delphi survey by the Italian Association of Hospital Gastroenterologists (A.I.G.O.). J Hepatol 2005; 43 (3): 381-387. (Pubitemid 41111417)
27. Muir AJ, Trotter JF,. A survey of current liver biopsy practice patterns. J Clin Gastroenterol 2002; 35 (1): 86-88. (Pubitemid 34663357)
28. Castera L, Denis J, Babany G, Roudot-Thoraval F,. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines? J Hepatol 2007; 46 (3): 528-529; author reply 9-30. (Pubitemid 46201725)
29. [No authors listed]. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36 (5 Suppl. 1): S3-S20.
30. McCaughan GW, Omata M, Amarapurkar D, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007; 22 (5): 615-633. (Pubitemid 46608388)
31. [No authors listed]. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. Dig Liver Dis 2010; 42 (2): 81-91.
32. Craxi A,. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55 (2): 245-64.
33. Manning DS, Afdhal NH,. Diagnosis and quantitation of fibrosis. Gastroenterology 2008; 134 (6): 1670-1681. (Pubitemid 351615414)
34. Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J,. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996; 42 (4): 558-563. (Pubitemid 26111874)
35. Halfon P, Bourliere M, Penaranda G, et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol 2005; 4: 6.
36. McHutchison JG, Blatt LM, de Medina M, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 2000; 15 (8): 945-951.
37. Misaki M, Shima T, Yano Y, et al. Basement membrane-related and type III procollagen-related antigens in serum of patients with chronic viral liver disease. Clin Chem 1990; 36 (3): 522-524.
38. Oberti F, Valsesia E, Pilette C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997; 113 (5): 1609-1616. (Pubitemid 27461247)
39. Walsh KM, Fletcher A, MacSween RN, Morris AJ,. Basement membrane peptides as markers of liver disease in chronic hepatitis C. J Hepatol 2000; 32 (2): 325-330. (Pubitemid 30093913)
40. Saitou Y, Shiraki K, Yamanaka Y, et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005; 11 (4): 476-481. (Pubitemid 40185578)
41. Cales P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42 (6): 1373-1381. (Pubitemid 43260040)
42. Leroy V, Hilleret MN, Sturm N, et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46 (5): 775-782. (Pubitemid 46529041)
43. Patel K, Gordon SC, Jacobson I, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004; 41 (6): 935-942. (Pubitemid 39575660)
44. Christensen C, Bruden D, Livingston S, et al. Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients. J Viral Hepat 2006; 13 (10): 652-658. (Pubitemid 44401193)
45. Zaman A, Rosen HR, Ingram K, Corless CL, Oh E, Smith K,. Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med 2007; 120 (3): 280.e9-280.e14.
46. Patel K, Nelson DR, Rockey DC, et al. Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Clin Gastroenterol Hepatol 2008; 6 (2): 242-247.
47. Mehta P, Ploutz-Snyder R, Nandi J, Rawlins SR, Sanderson SO, Levine RA,. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2008; 103 (4): 928-936. (Pubitemid 351501097)
48. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51 (10): 1867-1873. (Pubitemid 41368177)
49. Becker L, Salameh W, Sferruzza A, et al. Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol 2009; 7 (6): 696-701.
50. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127 (6): 1704-1713. (Pubitemid 39575849)
51. Giannini E, Risso D, Botta F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003; 163 (2): 218-224. (Pubitemid 36120190)
52. Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005; 41 (6): 1376-1382. (Pubitemid 40770291)
53. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38 (2): 518-526. (Pubitemid 36919874)
54. Sebastiani G, Vario A, Guido M, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006; 44 (4): 686-693.
55. Shaheen AA, Myers RP,. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46 (3): 912-921. (Pubitemid 47436137)
56. Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005; 42 (2): 282-292. (Pubitemid 41061080)
57. Castera L, Le Bail B, Roudot-Thoraval F, et al. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J Hepatol 2009; 50 (1): 59-68.
58. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36 (4 Pt 1): 986-992.
59. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46 (1): 32-36. (Pubitemid 47171918)
60. Adler M, Gulbis B, Moreno C, et al. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases. Hepatology 2008; 47 (2): 762-763; author reply 3. (Pubitemid 351280750)
61. Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC gastroenterol 2007; 7: 40.
62. Sebastiani G,. Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms. World J Gastroenterol 2009; 15 (18): 2190-2203.
63. Sebastiani G, Vario A, Guido M, Alberti A,. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat 2008; 15 (3): 212-218. (Pubitemid 351143742)
64. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128 (2): 343-350. (Pubitemid 40439195)
65. Halfon P, Bourliere M, Deydier R, et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006; 101 (3): 547-555. (Pubitemid 43340931)
66. Halfon P, Bacq Y, De Muret A, et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46 (3): 395-402. (Pubitemid 46201720)
67. Bourliere M, Penaranda G, Ouzan D, et al. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients. Aliment Pharmacol Ther 2008; 28 (4): 458-467. (Pubitemid 352033276)
68. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T,. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357 (9262): 1069-1075. (Pubitemid 32322537)
69. Shaheen AA, Wan AF, Myers RP,. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007; 102 (11): 2589-2600. (Pubitemid 47631778)
70. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29 (12): 1705-1713. (Pubitemid 38091720)
71. Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010; 53 (6): 1013-1021.
72. Cross TJ, Calvaruso V, Maimone S, et al. Prospective comparison of Fibroscan, King's score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection. J Viral Hepat 2010; 17 (8): 546-554.
73. Arena U, Vizzutti F, Abraldes JG, et al. Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut 2008; 57 (9): 1288-1293.
74. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41 (1): 48-54. (Pubitemid 40066382)
75. Kettaneh A, Marcellin P, Douvin C, et al. Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol 2007; 46 (4): 628-634. (Pubitemid 46420381)
76. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134 (4): 960-974.
77. Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56 (7): 968-973. (Pubitemid 46999083)
78. Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51 (3): 828-835.
79. Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008; 47 (2): 380-384. (Pubitemid 351280705)
80. Millonig G, Reimann FM, Friedrich S, et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 2008; 48 (5): 1718-1723.
81. Lebray P, Varnous S, Charlotte F, Varaut A, Poynard T, Ratziu V,. Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency. Hepatology 2008; 48 (6): 2089.
82. Lucidarme D, Foucher J, Le Bail B, et al. Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49 (4): 1083-1089.
83. Sebastiani G, Halfon P, Castera L, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49 (6): 1821-1827.
84. Castera L, Sebastiani G, Le Bail B, de Ledinghen V, Couzigou P, Alberti A,. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52 (2): 191-198.
85. Bourliere M, Penaranda G, Renou C, et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat 2006; 13 (10): 659-670. (Pubitemid 44401194)
86. Boursier J, Cales P,. Combination of fibrosis tests: sequential or synchronous? Hepatology 2009; 50 (2): 656-657; author reply 7.
87. Pinzani M, Vizzutti F, Arena U, Marra F,. Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol 2008; 5 (2): 95-106. (Pubitemid 351234279)
88. Shiha G, Sarin SK, Ibrahim AE, et al. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hep Intl 2009; 3 (2): 323-333.
89. Cales P, Laine F, Boursier J, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009; 50 (1): 165-173.
90. Halfon P, Munteanu M, Poynard T,. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol 2008; 6 (Suppl. 1): 22-39.
91. Cales P, Boursier J, Bertrais S, et al. Optimization and robustness of blood tests for liver fibrosis and cirrhosis. Clin Biochem 2010; 17: 1315-1322.
92. Boursier J, Vergniol J, Sawadogo A, et al. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int 2009; 29 (10): 1507-1515.
93. Sebastiani G, Alberti A,. Implementing non-invasive markers for liver fibrosis in clinical practice. J Hepatol 2008; 48 (5): 880-881; author reply 1-3.